VelaVigo was founded by Dr. Jing Li, a renowned biopharma executive, in October 2021. We leverage discovery as an innovative engine with an emphasis on novel technologies, including bispecific/multi-specific antibodies, ADC, and new modalities. We are committed to building full capabilities covering the entire value chain of drug discovery and development, including novel discovery technology platform, translational medicine, CMC, clinical development and commercialization. VelaVigo is building its global R&D headquarter in Shanghai, and will set up R&D footprint globally. VelaVigo combines internal discovery/development and win-win partnership to drive its portfolio. We strive to the development of innovative, affordable biological drugs to address unmet clinical needs for global patients.
Company Details
- Employees
- 18
- Founded
- 2021
- Address
- Shanghai, Prc 200131, Cn
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.velavigo.com/+
- Keywords
- Biologics Drug Discovery and Development, ADC, New Modalities, Bispecific/Multi-specific Antibodies.
- HQ
- Shanghai, PRC
Velavigo Questions
Velavigo's website is http://www.velavigo.com/+
Velavigo's LinkedIn profile is https://cn.linkedin.com/company/velavigo
Velavigo has
18 employees.
View email and phone details for 18
employees at Velavigo.
Velavigo's industry is
Biotechnology Research
Velavigo's top competitors are
Xyone Therapeutics Inc.,
Sparx Biopharmaceutical Corp,
Avenzo Therapeutics,
Artbio,
Ollin Biosciences,
Neox Biotech,
Renasant Bio,
Thelper,
Maplight Therapeutics, Inc.,
Remegen Biosciences.
Velavigo's categories are Biotechnology Research
Velavigo's founding year is 2021
